

National Phase Entry of
International Application No.:
PCT/GB97/02108 which was filed:
August 5, 1997

Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1300 (Our Order No. A-67653/RFT/AMS).

In the claims:

Please amend the claims as follows:

C1
Sub 1
1. (TWICE AMENDED) A method of screening for a premalignant or neoplastic disease state in a cervical smear sample containing cells of the cervix, the method comprising contacting a panel of two or more monoclonal antibodies with said sample, each antibody having specificity for a different antigen of said sample relative to the other antibodies in said sample, determining binding of said monoclonal antibodies to said sample and comparing the binding with a pattern of binding of said monoclonal antibodies to a normal cervical cell sample, wherein said monoclonal antibodies detect cellular markers which differ between normal and premalignant or neoplastic cells.

Sub E2
C2
3. (TWICE AMENDED) A method of determining a premalignant or neoplastic disease state in a cervical smear sample containing cells of the cervix, the method comprising contacting one or more monoclonal antibodies with said sample, determining binding of said monoclonal antibodies to said sample and comparing the binding with a pattern of binding of said monoclonal antibodies to a normal cervical cell sample, wherein said monoclonal antibodies detect cellular markers which differ between normal and premalignant or neoplastic cells and wherein the monoclonal antibodies comprise one or more polypeptides each comprising an antigen binding domain obtained from a hybridoma selected from those deposited at the European Collection of Animal Cell Cultures (ECACC), under the accession numbers ECACC 95020718, ECACC 95020716, ECACC 95020720, ECACC 95020717 and ECACC 95020719.